Trypanosoma Cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (amotosalen HCl) and Long-wavelength UV

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2003 Jan 25

PMID 12543646

Citations 21

Authors

Wesley C Van Voorhis

Lynn K Barrett

Richard T Eastman

Ryan Alfonso

Kent Dupuis

Affiliations

Soon will be listed here.

Abstract

Trypanosoma cruzi, the protozoan pathogen that causes Chagas' disease, can be found in the blood of infected individuals for their entire life span. This presents a serious challenge in safeguarding blood products. Transmission of T. cruzi from blood products is a frequent occurrence in Latin America, where Chagas' disease is endemic. This study was designed to determine whether T. cruzi could be inactivated in human platelet concentrates and plasma by a photochemical treatment process with long-wavelength UV A light (UVA, 320 to 400 nm) plus the psoralen amotosalen HCl (Cerus Corporation). Units of platelet concentrates (300 ml) and plasma (300 ml) were intentionally contaminated with approximately 10(6) T. cruzi trypomastigotes, the T. cruzi form found in the bloodstream, per ml. The viability of T. cruzi after photochemical inactivation was determined by their ability to replicate in 3T3 fibroblasts. Controls, including treatment with 150 micro M amotosalen or 3 J/cm(2) UVA alone, did not lead to reduction of the viability of T. cruzi in plasma or platelet concentrates. However, treatment with 150 micro M amotosalen plus 3 J/cm(2) UVA inactivated T. cruzi to undetectable levels in plasma and platelet concentrates. This represented a >5.4-log reduction of T. cruzi in platelet concentrates and >5.0-log reduction of T. cruzi in plasma. We conclude that the amotosalen plus UVA photochemical inactivation technology is effective in inactivating high levels of protozoan pathogens, such as T. cruzi, in platelet concentrates and plasma, as has been previously shown for numerous viruses and bacteria.

Citing Articles

Complete Inactivation of Blood Borne Pathogen in Stored Human Platelet Concentrates and Plasma Treated With 405 nm Violet-Blue Light.

Jankowska K, Nagarkatti R, Acharyya N, Dahiya N, Stewart C, Macpherson R Front Med (Lausanne). 2020; 7:617373.

PMID: 33330577 PMC: 7732587. DOI: 10.3389/fmed.2020.617373.

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.

Lanteri M, Santa-Maria F, Laughhunn A, Girard Y, Picard-Maureau M, Payrat J Transfusion. 2020; 60(6):1319-1331.

PMID: 32333396 PMC: 7317863. DOI: 10.1111/trf.15807.

Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Domanovic D, Ushiro-Lumb I, Compernolle V, Brusin S, Funk M, Gallian P Blood Transfus. 2019; 17(6):433-448.

PMID: 31846608 PMC: 6917531. DOI: 10.2450/2019.0288-19.

Trypanosoma cruzi infection in transfusion medicine.

Gomez L, Gutierrez F, Penuela O Hematol Transfus Cell Ther. 2019; 41(3):262-267.

PMID: 31085149 PMC: 6732405. DOI: 10.1016/j.htct.2018.12.001.

Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland.

Niederhauser C, Gottschalk J, Tinguely C Transfus Med Hemother. 2016; 43(3):169-76.

PMID: 27403088 PMC: 4924468. DOI: 10.1159/000446218.

References

Schmunis G . Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem Inst Oswaldo Cruz. 2000; 94 Suppl 1:93-101. DOI: 10.1590/s0074-02761999000700010. View

NUSSENZWEIG V, SONNTAG R, BIANCALANA A, DE FREITAS J, AMATO NETO V, KLOETZEL J . [Effect of triphenylmethane dyes on Trypanosoma cruzi in vitro; use of gentian violet in prevention of transmission of Chagas disease by blood transfusion]. Hospital (Rio J). 1953; 44(6):731-44. View

Chapman J . Progress in improving the pathogen safety of red cell concentrates. Vox Sang. 2000; 78 Suppl 2:203-4. View

Skripchenko A, Wagner S . Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB. Transfusion. 2000; 40(8):968-75. DOI: 10.1046/j.1537-2995.2000.40080968.x. View

Leiby D, Rentas F, Nelson K, Stambolis V, Ness P, Parnis C . Evidence of Trypanosoma cruzi infection (Chagas' disease) among patients undergoing cardiac surgery. Circulation. 2000; 102(24):2978-82. DOI: 10.1161/01.cir.102.24.2978. View

Snyder E, Dodd R . Reducing the risk of blood transfusion. Hematology Am Soc Hematol Educ Program. 2001; :433-42. DOI: 10.1182/asheducation-2001.1.433. View

Schmunis G, Zicker F, CRUZ J, Cuchi P . Safety of blood supply for infectious diseases in Latin American countries, 1994-1997. Am J Trop Med Hyg. 2002; 65(6):924-30. DOI: 10.4269/ajtmh.2001.65.924. View

Reed S . In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol. 1988; 140(12):4342-7. View

Sturm N, Degrave W, Morel C, Simpson L . Sensitive detection and schizodeme classification of Trypanosoma cruzi cells by amplification of kinetoplast minicircle DNA sequences: use in diagnosis of Chagas' disease. Mol Biochem Parasitol. 1989; 33(3):205-14. DOI: 10.1016/0166-6851(89)90082-0. View

10.

Moser D, Kirchhoff L, Donelson J . Detection of Trypanosoma cruzi by DNA amplification using the polymerase chain reaction. J Clin Microbiol. 1989; 27(7):1477-82. PMC: 267598. DOI: 10.1128/jcm.27.7.1477-1482.1989. View

11.

Grant I, Gold J, Wittner M, Tanowitz H, Nathan C, Mayer K . Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med. 1989; 111(10):849-51. DOI: 10.7326/0003-4819-111-10-849. View

12.

. Control of Chagas disease. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1991; 811:1-95. View

13.

Kirchhoff L . American trypanosomiasis (Chagas' disease)--a tropical disease now in the United States. N Engl J Med. 1993; 329(9):639-44. DOI: 10.1056/NEJM199308263290909. View

14.

Avila H, Pereira J, Thiemann O, de Paiva E, Degrave W, Morel C . Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. J Clin Microbiol. 1993; 31(9):2421-6. PMC: 265772. DOI: 10.1128/jcm.31.9.2421-2426.1993. View

15.

Cimo P, Luper W, Scouros M . Transfusion-associated Chagas' disease in Texas: report of a case. Tex Med. 1993; 89(12):48-50. View

16.

Centurion-Lara A, Barrett L, Van Voorhis W . Quantitation of parasitemia by competitive polymerase chain reaction amplification of parasite kDNA minicircles during chronic infection with Trypanosoma cruzi. J Infect Dis. 1994; 170(5):1334-9. DOI: 10.1093/infdis/170.5.1334. View

17.

Galel S, Kirchhoff L . Risk factors for Trypanosoma cruzi infection in California blood donors. Transfusion. 1996; 36(3):227-31. DOI: 10.1046/j.1537-2995.1996.36396182140.x. View

18.

Lin L, Cook D, Wiesehahn G, Alfonso R, Behrman B, Cimino G . Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997; 37(4):423-35. DOI: 10.1046/j.1537-2995.1997.37497265344.x. View

19.

Shulman I, APPLEMAN M, Saxena S, Hiti A, Kirchhoff L . Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion. 1997; 37(7):727-31. DOI: 10.1046/j.1537-2995.1997.37797369449.x. View

20.

Leiby D, Read E, Lenes B, Yund A, Stumpf R, Kirchhoff L . Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis. 1997; 176(4):1047-52. DOI: 10.1086/516534. View